Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.

Abstract:

:Outcomes in patients with secondary acute myeloid leukemia (sAML) (including therapy related myeloid neoplasms and AML with myelodysplasia related changes (MRC)) are poor. Patients treated with hypomethylating agents (HMAs) for antecedent hematological malignancy (AHM) have suboptimal responses to induction chemotherapy upon transformation to AML. We investigated outcomes after various induction strategies in patients with sAML who had prior HMA exposure. We identified 242 patients with sAML who had prior HMA treatment for AHM and later received induction chemotherapy upon AML transformation and divided into 3 cohorts based on induction regimen: (A) CLAG/M (B) 7 + 3 and (C) CPX-351. The CR/CRi rate was 53% in cohort A, 32% in cohort B and 41.2% in cohort C (p = 0.005 between cohort A and B) (p = 0.329 between cohorts A and C) (p = 0.402 between cohorts B and C). The early death rates were not significantly different among the three cohorts (p = 0.200). In patients who received ≤4 cycles of HMAs prior to AML transformation, response rates to CPX-351 were higher (64.3%) with a trend toward better overall survival (OS) (19.9 vs. 5.5 months) compared to >4 cycles (p = 0.092). There was no significant difference in median OS among the 3 groups: cohort A (7.27 months), cohort B (7.63 months) and cohort C (7.07 months) (p = 0.887). We demonstrate that CLAG/M and CPX-351 yield higher CR/CRi rates compared to 7 + 3 in patients with sAML after HMA failure. Median OS remains poor and did not differ among the 3 groups, illustrating the unmet need for more efficacious therapy for sAML patients following HMA failure.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Talati C,Goldberg AD,Przespolewski A,Chan O,Ali NA,Kim J,Famulare C,Sallman D,Padron E,Kuykendall A,Lancet JE,Wang E,Tallman MS,Komrokji R,Sweet K

doi

10.1016/j.leukres.2020.106367

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

106367

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(20)30072-2

journal_volume

93

pub_type

杂志文章,多中心研究
  • Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells.

    abstract::The use of low density lipoprotein (LDL) as drug carrier in acute myeloblastic leukemia chemotherapy is attractive due to high LDL uptake by leukemic cells. Lipid-based formulations, such as liposomes or microemulsions are promising alternatives. In the current study, we incorporated N-trifluoroacetyl-adriamycin-14-va...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.06.012

    authors: Masquelier M,Lundberg B,Peterson C,Vitols S

    更新日期:2006-02-01 00:00:00

  • Effects of X-irradiation, ovariohysterectomy and estradiol-17 beta on incidence, benign/malignant ratio and multiplicity of rat mammary neoplasms--a preliminary report.

    abstract::An overview is given of the effects of X-irradiation, ovariohysterectomy and estradiol-17 beta administration on mammary tumorigenesis in females of 3 rat strains, viz. the WAG/Rij, BN/BiRij and SD. The 3 rat strains differed significantly in their spontaneous mammary tumor incidence. Female SD rats had the highest in...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(86)90292-4

    authors: Solleveld HA,van Zwieten MJ,Broerse JJ,Hollander CF

    更新日期:1986-01-01 00:00:00

  • Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

    abstract::Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.03.015

    authors: Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

    更新日期:2015-07-01 00:00:00

  • Inhibition of sonic hedgehog signaling blocks cell migration and growth but induces apoptosis via suppression of FOXQ1 in natural killer/T-cell lymphoma.

    abstract::The present study explored the effects of Forkhead box Q1 (FOXQ1) on cell proliferation, cell cycle and apoptosis via the Sonic hedgehog (Shh) pathway in Natural killer/T-cell lymphoma (NKTCL). Quantitative real time-polymerase chain reaction (qRT-PCR) was performed to detect FOXQ1 expression in 117 NKTCL patients and...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.11.001

    authors: Liu P,Chen L

    更新日期:2018-01-01 00:00:00

  • Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.

    abstract::To clarify whether expression of the programmed cell death 5 (PDCD5) gene in leukemic cells is abnormal, real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) was used to examine its expression in marrow cells from leukemia patients. We found lower PDCD5 in both AML and CML marrow cells th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.12.028

    authors: Ruan GR,Qin YZ,Chen SS,Li JL,Ma X,Chang Y,Wang YZ,Fu JY,Liu YR

    更新日期:2006-09-01 00:00:00

  • KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.

    abstract::Gain-of-function mutations in the proto-oncogene c-kit that induce constitutive kinase activity of its product, KIT protein, are characteristic of human mast cell disease and are believed to play a central role in mast cell leukemia oncogenesis, proliferation and survival. Nuclear overexpression of the Wnt effector be...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.08.023

    authors: Kajiguchi T,Lee S,Lee MJ,Trepel JB,Neckers L

    更新日期:2008-05-01 00:00:00

  • Infectious feline leukaemia virus is erythrosuppressive in vitro.

    abstract::The direct effect of the feline leukaemia virus (FeLV) on erythroid colony formation in vitro was investigated. Bone marrow mononuclear cells (BMMC) from FeLV-naïve, specific-pathogen-free (SPF), adult cats were inoculated with FeLVs of characterized strains and biologically cloned subgroups and the subsequent develop...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(86)90237-7

    authors: Rojko JL,Cheney CM,Gasper PW,Hamilton KL,Hoover EA,Mathes LE,Kociba GJ

    更新日期:1986-01-01 00:00:00

  • Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

    abstract::This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.08.009

    authors: Lee SS,Lee JH,Lee JH,Kim DY,Kim SH,Lim SN,Lee YS,Seol M,Ryu SG,Kang YA,Jang S,Park CJ,Chi HS,Yun SC,Lee KH

    更新日期:2009-04-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract::We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(97)00135-5

    authors: Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期:1998-01-01 00:00:00

  • Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias.

    abstract::Checkpoint genes code for a family of proteins which sense DNA damage in eukaryotic cells. They play an important role in the control of the cell cycle. The human CHK2 is a homolog of the yeast G(2) checkpoint kinases known as CDS1 and RAD53. The CHK2 may be a tumor suppressor gene because it was found to be mutated i...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(00)00130-2

    authors: Hofmann WK,Miller CW,Tsukasaki K,Tavor S,Ikezoe T,Hoelzer D,Takeuchi S,Koeffler HP

    更新日期:2001-04-01 00:00:00

  • Angiogenic factors in chronic lymphocytic leukemia.

    abstract::Angiogenesis is a complex process controlled by the balance of a large number of regulating factors, the pro- and anti-angiogenic factors. Dysregulation of angiogenesis occurs in various pathologies and is one of the hallmarks for cancer. Recent emphasis on the microenvironment's influence in chronic lymphocytic leuke...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2012.05.021

    authors: Xia Y,Lu RN,Li J

    更新日期:2012-10-01 00:00:00

  • Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.

    abstract::Mutation of the tumor suppressor PTEN results in loss of its PI3-kinase counteracting function. PI3-kinase stimulates tumor formation by PKB/Akt-mediated cell proliferation and prevention of apoptosis. PI3-kinase may also activate Rho-GTPases and their regulatory GEFs to promote invasion. Here we have analyzed the fun...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.03.034

    authors: Strumane K,Song JY,Baas I,Collard JG

    更新日期:2008-01-01 00:00:00

  • Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.

    abstract::Osteogenic growth peptide (OGP) is a peptide exerting regulatory effects on the bone and on bone marrow. The carboxy-terminal pentapeptide (OGP10-14) is the biologically active portion of OGP. We evaluated OGP10-14 hematopoietic activity performing colony-forming tests on human stem cells derived by bone marrow, perip...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00008-5

    authors: Fazzi R,Galimberti S,Testi R,Pacini S,Trasciatti S,Rosini S,Petrini M

    更新日期:2002-09-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract::Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0145-2126(96)00116-6

    authors: Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期:1997-02-01 00:00:00

  • Neuroleukin mediated differentiation induction of myelogenous leukemia cells.

    abstract::Leukemia cells enriched from peripheral blood of a patient with myelogenous leukemia were induced to differentiate with a purified T cell lymphokine neuroleukin. With sufficient neuroleukin concentrations, cells with macrophage-like morphology were identified among the developing adherent cells. After 2-5 days, approx...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00129-5

    authors: Chiao JW,Xu W,Seiter K,Feldman E,Ahmed T

    更新日期:1999-01-01 00:00:00

  • Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

    abstract::We compared the growth-inhibitory effects and inhibition profile of the SRC family kinases (SFKs) of imatinib, dasatinib, nilotinib and INNO-406. Dasatinib exhibited the strongest potency against BCR-ABL with little selectivity over SFKs. Nilotinib exhibited a weaker affinity than the other inhibitors, but was highly ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.11.008

    authors: Deguchi Y,Kimura S,Ashihara E,Niwa T,Hodohara K,Fujiyama Y,Maekawa T

    更新日期:2008-06-01 00:00:00

  • The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529.

    abstract::Ras proteins are frequently over-expressed in leukemia and contribute to leukemogenesis. We evaluated the anti-leukemic efficacy of a new third-generation bisphosphonate, ONO5920/YM529 (YM529). YM529 prevents the prenylation of Ras proteins and inhibited the growth of leukemic cells including a P-glycoprotein (P-gp) o...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.10.004

    authors: Segawa H,Kimura S,Kuroda J,Sato K,Nogawa M,Yuasa T,Yokota A,Hodohara K,Fujiyama Y,Maekawa T

    更新日期:2005-04-01 00:00:00

  • Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.

    abstract::We have recently described that a variant of L1210 leukemia cell (L1210/LN-1) originally fused with Lesch-Nyhan fibroblast is highly immunogenic for inducing tumor-specific transplantation immunity in (BALB/cxDBA/2)F1 mice. This finding has clearly been confirmed in the present study by in-vitro cell-mediated cytotoxi...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(85)90316-9

    authors: Kawashima K,Isobe K,Nagase F,Yokochi T,Nagura E,Hasegawa Y,Morishita H,Yamada K,Nakashima I

    更新日期:1985-01-01 00:00:00

  • Characterization of a 4 lncRNAs-based prognostic risk scoring system in adults with acute myeloid leukemia.

    abstract:PURPOSE:The study aims to develop a prognostic scoring system based on prognostic lncRNAs for acute myeloid leukemia (AML). METHODS:Based on lncRNA expression profiles downloaded from The Cancer Genome Atlas (TCGA), differentially expressed long noncoding RNAs (DELs) between good prognosis and bad prognosis samples we...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2019.106261

    authors: Zeng H,Wu H,Yan M,Tang L,Guo X,Zhao X

    更新日期:2020-01-01 00:00:00

  • Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

    abstract::Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2013.01.004

    authors: Adès L,Sekeres MA,Wolfromm A,Teichman ML,Tiu RV,Itzykson R,Maciejewski JP,Dreyfus F,List AF,Fenaux P,Komrokji RS

    更新日期:2013-06-01 00:00:00

  • Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

    abstract::Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in treatment decisions. We examined 280 newly diagnosed higher-risk elderly MDS patients paired with ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.05.012

    authors: Caocci G,Voso MT,Angelucci E,Stauder R,Cottone F,Abel G,Nguyen K,Platzbecker U,Beyne-Rauzy O,Gaidano G,Invernizzi R,Molica S,Criscuolo M,Breccia M,Lübbert M,Sanpaolo G,Buccisano F,Ricco A,Palumbo GA,Niscola P,Zhan

    更新日期:2015-08-01 00:00:00

  • Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

    abstract::We investigated the role of Src family kinases (SFKs) in the regulation of STAT activation in myeloid leukemia cells. Two of 6 AML cell lines displayed constitutive STAT5 activation, whereas four cell lines had constitutive SFK activity. Treatment with the SFK inhibitors suppressed STAT5 activation and decreased viabi...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.11.032

    authors: Ozawa Y,Williams AH,Estes ML,Matsushita N,Boschelli F,Jove R,List AF

    更新日期:2008-06-01 00:00:00

  • Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL).

    abstract::MicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the post-transcriptional level through its sequence complementation with target mRNAs. An individual miRNA species can simultaneously influence the expression of multiple genes and conversely, several miRNAs can synchronously contro...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2013.08.020

    authors: Mazan-Mamczarz K,Gartenhaus RB

    更新日期:2013-11-01 00:00:00

  • Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature.

    abstract::Granulocytic sarcoma (GS) is a rare extra-medullary tumor and usually involves the skin, soft tissue, and lymph nodes. GS is found in 8% of acute myeloid leukemia (AML) patients, especially patients with t(8;21)AML. It has been suggested that GS is a poor prognostic factor in t(8;21)AML. Compared to t(8;21)AML, GS is ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.11.003

    authors: Fujieda A,Nishii K,Tamaru T,Otsuki S,Kobayashi K,Monma F,Ohishi K,Nakase K,Katayama N,Shiku H

    更新日期:2006-08-01 00:00:00

  • Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells.

    abstract::We evaluated the molecular mechanism of telomerase activation by erythropoietin (EPO) in human erythroleukemic JAS-REN-A cells. Telomerase activity increased 3-4 fold after 3-24h of culture with EPO and was associated with increases in c-myc mRNA after 1-3h, of c-Myc protein after 3-6h, and of human telomerase reverse...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.11.002

    authors: Akiyama M,Kawano T,Mikami-Terao Y,Agawa-Ohta M,Yamada O,Ida H,Yamada H

    更新日期:2011-03-01 00:00:00

  • Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

    abstract::Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...

    journal_title:Leukemia research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.leukres.2018.07.024

    authors: Ferraro F,Gao F,Stockerl-Goldstein K,Westervelt P,DiPersio JF,Ghobadi A

    更新日期:2018-09-01 00:00:00

  • Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).

    abstract::The resistance to all trans retinoic acid (ATRA) differentiating treatment is a consequence, in most of the cases, of either increased catabolism or down regulation of ATRA uptake. Recently, we have shown that ATRA efficiency to differentiate HL-60 cells was enhanced about 30 times after its incorporation into Low Den...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(00)00019-9

    authors: Gueddari N,Madoulet C,Lefebvre P,Berthou L,Chomienne C,Jardillier JC

    更新日期:2000-06-01 00:00:00

  • WITHDRAWN: The effect of dihydroartemisinin on TfR and VEGF expression in iron overload human myeloid leukemia K562 cells.

    abstract::This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.01.006

    authors: Zengwang,Zhou HJ,Li A,Zhang JL

    更新日期:2009-02-20 00:00:00

  • Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.

    abstract:BACKGROUND:Better risk-stratification of patients with chronic lymphocytic leukemia (CLL) and identification of subsets of ultra-high-risk (HR)-CLL patients are crucial in the contemporary era of an expanded therapeutic armamentarium for CLL. METHODS:A multivariate patient similarity network and clustering was applied...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2019.02.005

    authors: Turcsanyi P,Kriegova E,Kudelka M,Radvansky M,Kruzova L,Urbanova R,Schneiderova P,Urbankova H,Papajik T

    更新日期:2019-04-01 00:00:00

  • Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation.

    abstract::miR-16, a miRNA involved in cell proliferation and apoptosis regulation, may interfere with either oncogenic or tumor-suppressor pathways and is implicated in leukemogenesis. We then explored its expression in 93 childhood acute lymphoblastic leukemia (ALL) cases. A high miR-16 expression was associated with hyperleuk...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2008.12.015

    authors: Kaddar T,Chien WW,Bertrand Y,Pages MP,Rouault JP,Salles G,Ffrench M,Magaud JP

    更新日期:2009-09-01 00:00:00